Literature DB >> 26665675

[Relationship between TMPRSS2: ERG and the pathological grade of prostate cancer].

Fa-xian Yi, Hong Li, Qiang Wei, Xiang Li, Hao Zeng.   

Abstract

OBJECTIVE: To study the relationship between TMPRSS2: ERG gene fusion and the pathological grade of prostate cancer (PCa).
METHODS: We collected fresh prostatic tissue samples from 62 patients with PCa and another 10 with benign prostatic hyperplasia ( BPH) and included 9 cancer cell strains as the control. We examined the TMPRSS2:ERG fusion gene in the PCa samples by nest RT-PCR, compared the Gleason scores between the TMPRSS2:ERG-positive and -negative cases, and analyzed the association of TMPRSS2: ERG fusion with the pathological features of PCa.
RESULTS: The TMPRSS2: ERG fusion gene was detected in 28 (45.16%) of the PCa cases, but in none of the 10 BPH cases or the 9 cancer cell strains. No statistically significant differences were found in the Gleason scores between the TMPRSS2:ERG-positive and -negative cases (Z = -0.609, P = 0.542), but the primary Gleason score was markedly higher in the former than in the latter (Z = -2.600, P = 0.009). Univariate logistic regression analysis showed that TMPRSS2:ERG was associated with the cribriform growth pattern (OR = 6.250, P = 0.002), foamy gland morphology (OR = 6.666, P = 0.023), and signet-ring cells (OR = 3.240, P = 0.035), but multivariate logistic regression analysis manifested that it was associated with the cribriform growth pattern only (OR = 3.750, P = 0.033).
CONCLUSION: TMPRSS2:ERG gene fusion was associated with higher pathological grades of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26665675

Source DB:  PubMed          Journal:  Zhonghua Nan Ke Xue        ISSN: 1009-3591


  1 in total

1.  Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review.

Authors:  De-Pei Kong; Rui Chen; Chun-Lei Zhang; Wei Zhang; Guang-An Xiao; Fu-Bo Wang; Na Ta; Xu Gao; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2020 Mar-Apr       Impact factor: 3.285

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.